Ta de Clinicagem tadeclinicagem

Rapha, Leticia e Lucca discutem 7 armadilhas na doença do refluxo gastroesofageana (DRGE)!



Referências:

1. Fass, Ronnie. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 387,13 (2022): 1207-1216.

2. Parmar, Malvinder S. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 388,9 (2023): 863.

3. Jenkins, Danny, and Ines Modolell. “Proton pump inhibitors.” BMJ (Clinical research ed.) vol. 383 e070752. 13 Nov. 2023.

4. Katzka, David A, and Peter J Kahrilas. “Advances in the diagnosis and management of gastroesophageal reflux disease.” BMJ (Clinical research ed.) vol. 371 m3786. 23 Nov. 2020,

5. Barr J, Gulrajani NB, Hurst A, Pappas TN. Bottoms Up: A History of Rectal Nutrition From 1870 to 1920. Ann Surg Open. 2021;2(1):e039. Published 2021 Feb 10.

6.Fass, R et al. “Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.” Alimentary pharmacology & therapeutics vol. 29,12 (2009): 1261-72.

7. Lee, R. D., et al. "Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor–evidence for dosing flexibility." Alimentary pharmacology & therapeutics 29.8 (2009): 824-833.

8.Metz, D C et al. “Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.” Alimentary pharmacology & therapeutics vol. 29,7 (2009): 742-54.

9. Ip, Stanley, et al. Comparative Effectiveness of Management Strategies For Gastroesophageal Reflux Disease. Agency for Healthcare Research and Quality (US), December 2005.

10. Zhuang, Qianjun, et al. "Comparative efficacy of P-CABs versus proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis." Official journal of the American College of Gastroenterology| ACG (2022): 10-14309.

11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020839s078lbl.pdf
12. Iwakiri, Katsuhiko, et al. "Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021." Journal of gastroenterology 57.4 (2022): 267-285.
13. Graham, David Y., and Aylin Tansel. "Interchangeable use of proton pump inhibitors based on relative potency." Clinical Gastroenterology and Hepatology 16.6 (2018): 800-808.
14. Hatlebakk, J G et al. “Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily.” Alimentary pharmacology & therapeutics vol. 12,12 (1998): 1235-40.

15. Chen, Joan W., et al. "AGA clinical practice update on the diagnosis and management of extraesophageal gastroesophageal reflux disease: expert review." Clinical Gastroenterology and Hepatology (2023).
16. Gyawali, C. Prakash, et al. "Updates to the modern diagnosis of GERD: Lyon consensus 2.0." Gut 73.2 (2024): 361-371.
17. Katz, Philip O., et al. "ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease." Official journal of the American College of Gastroenterology| ACG 117.1 (2022): 27-56.
18. Hicks, Douglas M., et al. "The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers." Journal of Voice 16.4 (2002): 564-579.
19. Blondeau, Kathleen, et al. "Improved diagnosis of gastro‐oesophageal reflux in patients with unexplained chronic cough." Alimentary pharmacology & therapeutics 25.6 (2007): 723-732.

Rapha e Joanne conversam sobre dúvidas no manejo de pacientes com dengue: quando suspender DAPT? Quando suspender anticoagulantes? Quando internar por plaquetopenia? Quanto transfundir plaquetas? Devo usar coloide ou cristaloide?



Referências:
1. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Departamento de Doenças Transmissíveis. Dengue : diagnóstico e manejo clínico : adulto e criança [recurso eletrônico] / Ministério da
Saúde, Secretaria de Vigilância em Saúde e Ambiente, Departamento de Doenças Transmissíveis.– 6. ed. – Brasília : Ministério da Saúde, 2024. 81 p.: il.

Acesso: http://bvsms.saude.gov.br/bvs/publicacoes/dengue_diagnostico_manejo_clinico_6ed.pdf

2. Guidelines for the Clinical Diagnosis and Treatment of Dengue, Chikungunya, and Zika. Washington, D.C.: Pan American Health Organization; 2022. License: CC BY-NC-SA 3.0 IGO. https://doi.org/10.37774/9789275124871.

Trouxemos um trechinho do Curso TdC de Antibióticos aqui para o seu podcast! Quer assistir essa aula com imagens?
Faça sua pré-inscrição no link abaixo!
https://www.cursotdc.com.br/antibiotico/lead/

https://www.cursotdc.com.br/antibiotico/lead/
🎁 Faça a pré-inscrição e receba o Resumo do Tratamento de Pneumonia em PDF
🔴 Domine de vez a prescrição de antibióticos com o Curso TdC!✅ Antibioticoterapia voltada para a prática, sem detalhes desnecessários.

Marcela Belleza e Nathalie Santana conversam sobre quando repor testosterona.

Referências:
1. Layton, J Bradley et al. “Comparative Safety of Testosterone Dosage Forms.” JAMA internal medicine vol. 175,7 (2015): 1187-96. doi:10.1001/jamainternmed.2015.1573
2. Bhasin, Shalender et al. “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism vol. 103,5 (2018): 1715-1744. doi:10.1210/jc.2018-00229
3. Vigen, Rebecca et al. “Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.” JAMA vol. 310,17 (2013): 1829-36. doi:10.1001/jama.2013.280386
4. Bhasin, Shalender et al. “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism vol. 103,5 (2018): 1715-1744. doi:10.1210/jc.2018-00229
5. Corona, Giovanni et al. “Treatment of Functional Hypogonadism Besides Pharmacological Substitution.” The world journal of men's health vol. 38,3 (2020): 256-270. doi:10.5534/wjmh.190061
6. Corona, Giovanni et al. “European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology.” Andrology vol. 8,5 (2020): 970-987. doi:10.1111/andr.12770
7. Lincoff, A Michael et al. “Cardiovascular Safety of Testosterone-Replacement Therapy.” The New England journal of medicine vol. 389,2 (2023): 107-117. doi:10.1056/NEJMoa2215025

Kaue Malpighi convida Gabriel Paes e Amyr Chacar para falar de sedação e analgesia. Baseado em 4 casos, conversamos um pouco sobre meta de sedação, quais os principais sedativos, como fazer o despertar, quais analgésicos utilizar e muito mais.



🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨
🔴 Junte-se aos mais de 3.000 assinantes. Assine o Guia, ganhe tempo e atualize-se sem esforço.
🟠 Um serviço de revisão e atualização continuados em clínica médica. A informação que você precisa, do jeito que você prefere.
📚 Confira agora mesmo a edição aberta do Guia TdC sobre a nova diretriz de Insuficiência Cardíaca (IC) da American Heart Association (AHA): https://www.tadeclinicagem.com.br/guia/2/diretriz-de-insuficiencia-cardiaca-aha-2022/.



Referências:


Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299
Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet. 2010;375(9713):475-480. doi:10.1016/S0140-6736(09)62072-9
Olsen HT, Nedergaard HK, Strøm T, et al. Nonsedation or Light Sedation in Critically Ill, Mechanically Ventilated Patients. N Engl J Med. 2020;382(12):1103-1111. doi:10.1056/NEJMoa1906759
National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med. 2019;380(21):1997-2008. doi:10.1056/NEJMoa1901686
Walder B, Elia N, Henzi I, Romand JR, Tramèr MR. A lack of evidence of superiority of propofol versus midazolam for sedation in mechanically ventilated critically ill patients: a qualitative and quantitative systematic review. Anesth Analg. 2001;92(4):975-983. doi:10.1097/00000539-200104000-00033
Lewis K, Alshamsi F, Carayannopoulos KL, et al. Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials. Intensive Care Med. 2022;48(7):811-840. doi:10.1007/s00134-022-06712-2
Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med. 2012;186(8):724-731. doi:10.1164/rccm.201203-0522OC
Treggiari MM, Romand JA, Yanez ND, et al. Randomized trial of light versus deep sedation on mental health after critical illness. Crit Care Med. 2009;37(9):2527-2534. doi:10.1097/CCM.0b013e3181a5689f
Hughes CG, Girard TD, Pandharipande PP. Daily sedation interruption versus targeted light sedation strategies in ICU patients [published correction appears in Crit Care Med. 2013 Nov;41(11):e400]. Crit Care Med. 2013;41(9 Suppl 1):S39-S45. doi:10.1097/CCM.0b013e3182a168c5
Wheeler KE, Grilli R, Centofanti JE, et al. Adjuvant Analgesic Use in the Critically Ill: A Systematic Review and Meta-Analysis. Crit Care Explor. 2020;2(7):e0157. Published 2020 Jul 6. doi:10.1097/CCE.0000000000000157

https://www.cursotdc.com.br/antibiotico/lead/

🎁 Faça a pré-inscrição e receba o Resumo do Tratamento de Pneumonia em PDF

🔴 Domine de vez a prescrição de antibióticos com o Curso TdC! 

✅ Antibioticoterapia voltada para a prática, sem detalhes desnecessários.



Fred Amorim e João Mendes conversam sobre febre de Oropouche e outras arboviroses.

Referências:

1. Carpenter S, Groschup MH, Garros C, Felippe-Bauer ML, Purse BV. Culicoides biting midges, arboviruses and public health in Europe. Antiviral Res. 2013 Oct;100(1):102-13. doi: 10.1016/j.antiviral.2013.07.020. Epub 2013 Aug 8. PMID: 23933421.

2. Wesselmann KM, Postigo-Hidalgo I, Pezzi L, de Oliveira-Filho EF, Fischer C, de Lamballerie X, Drexler JF. Emergence of Oropouche fever in Latin America: a narrative review. Lancet Infect Dis. 2024 Jan 25:S1473-3099(23)00740-5. doi: 10.1016/S1473-3099(23)00740-5. Epub ahead of print. PMID: 38281494.

3. Durango-Chavez HV, Toro-Huamanchumo CJ, Silva-Caso W, Martins-Luna J, Aguilar-Luis MA, Del Valle-Mendoza J, Puyen ZM. Oropouche virus infection in patients with acute febrile syndrome: Is a predictive model based solely on signs and symptoms useful? PLoS One. 2022 Jul 26;17(7):e0270294. doi: 10.1371/journal.pone.0270294. PMID: 35881626; PMCID: PMC9321406.

4. Chiang JO, Azevedo RS, Justino MCA, Matos HJ, Cabeça HLS, Silva SP, Henriques DF, Silva EVP, Andrade GSS, Vasconcelos PF, Martins LC, Azevedo RSS. Neurological disease caused by Oropouche virus in northern Brazil: should it be included in the scope of clinical neurological diseases? J Neurovirol. 2021 Aug;27(4):626-630. doi: 10.1007/s13365-021-00987-9. Epub 2021 Jun 11. PMID: 34115330; PMCID: PMC8458178.

5. Travassos da Rosa JF, de Souza WM, Pinheiro FP, Figueiredo ML, Cardoso JF, Acrani GO, Nunes MRT. Oropouche Virus: Clinical, Epidemiological, and Molecular Aspects of a Neglected Orthobunyavirus. Am J Trop Med Hyg. 2017 May;96(5):1019-1030. doi: 10.4269/ajtmh.16-0672. Epub 2017 Feb 6. PMID: 28167595; PMCID: PMC5417190.

6. Vernal S, Martini CCR, da Fonseca BAL. Oropouche Virus-Associated Aseptic Meningoencephalitis, Southeastern Brazil. Emerg Infect Dis. 2019 Feb;25(2):380-382. doi: 10.3201/eid2502.181189. PMID: 30666950; PMCID: PMC6346467.

7. Mourãão MP, Bastos MS, Gimaqu JB, Mota BR, Souza GS, Grimmer GH, Galusso ES, Arruda E, Figueiredo LT. Oropouche fever outbreak, Manaus, Brazil, 2007-2008. Emerg Infect Dis. 2009 Dec;15(12):2063-4. doi: 10.3201/eid1512.090917. PMID: 19961705; PMCID: PMC3044544.

8. Vasconcelos PF, Calisher CH. Emergence of Human Arboviral Diseases in the Americas, 2000-2016. Vector Borne Zoonotic Dis. 2016 May;16(5):295-301. doi: 10.1089/vbz.2016.1952. Epub 2016 Mar 18. PMID: 26991057.

9. Bastos Mde S, Figueiredo LT, Naveca FG, Monte RL, Lessa N, Pinto de Figueiredo RM, Gimaque JB, Pivoto João G, Ramasawmy R, Mourão MP. Identification of Oropouche Orthobunyavirus in the cerebrospinal fluid of three patients in the Amazonas, Brazil. Am J Trop Med Hyg. 2012 Apr;86(4):732-5. doi: 10.4269/ajtmh.2012.11-0485. PMID: 22492162; PMCID: PMC3403753.